Pieris Pharmaceuticals, Inc.: Platform technology company developing Anticalins (engineered lipocalin proteins) for oncology and respiratory diseases. 2H18 Phase 1 data for: 1) fully-proprietary IO program PRS-343 for HER2+ solid tumors (targeting 4-1BB) and 2) AZN-partnered PRS-060 for moderate-to-severe asthma (targeting IL4RA through inhalation). I-O partnerships w Seattle Genetics and Servier.
Website:
Address:
255 State Street
Boston, MA 02109
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.